IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase
Jiang, Hao; Chen, Shan-Shan; Jiang, Bin; Jiang, Qian; Qin, Ya-Zhen; Lai, Yue-Yun; Huang, Xiao-Jun
关键词Chronic myeloid leukemia Imatinib Cytogenetic response Molecular response Event-free survival
刊名ANNALS OF HEMATOLOGY
2011
DOI10.1007/s00277-010-1031-0
90期:1页:41-46
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]CHRONIC MYELOID-LEUKEMIA ; ABL TYROSINE KINASE ; CYTOGENETIC RESPONSES ; FOLLOW-UP ; INTERFERON ; ALPHA ; CML ; INHIBITOR ; SURVIVAL ; MESYLATE
英文摘要

The purpose of our study is to compare the 7-year response to imatinib monotherapy as an initial treatment and re-treatment in Chinese patients with chronic myelogenous leukemia-chronic phase (CML-CP) patients in a single center in Beijing. A retrospective study of 171 CML-CP patients receiving imatinib monotherapy was done with 73 in the initial treatment group (disease course a parts per thousand currency sign6 months) and 98 in the re-treatment group (disease course > 6 months). Cumulative rates of complete cytogenetic response (CCyR) at 6, 12, and 36 months after imatinib treatment in the initial and re-treatment groups were 75%, 89%, and 96%, and 48%, 77% and 84% (p = 0.0002), respectively. The median time to CCyR in the initial and re-treatment groups was 6 months (95% CI, 3.3-8.3) and 9 months (95% CI, 6.4-11.6), respectively (p = 0.0002). Cumulative rates of major molecular responses at 9, 12, and 18 months after imatinib treatment in the initial and re-treatment groups were 31%, 48%, and 60%, and 15%, 25% and 37% (p = 0.017), respectively. The median time to the major molecular response in the initial and re-treatment groups was 15 months (95% CI, 12.3-17.7) and 36 months (95% CI, 25.9-46.0), respectively (p = 0.017). Progression-free survival at 84 months in the initial and re-treatment groups was 97% and 85%, respectively (p = 0.09). Event-free survival at 84 months in the initial and re-treatment groups was 92% and 70%, respectively (p = 0.049). Only two of the 171 patients discontinued imatinib therapy for grade 3/4 adverse events. Our study revealed that CML-CP patients would benefit from early treatment with imatinib.

语种英语
WOS记录号WOS:000285783800007
项目编号IRT 0702
资助机构program for innovative research team in the university
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67433
专题北京大学第二临床医学院_血液科
北京大学药学院_药事管理与临床药学系
北京大学临床肿瘤学院_移植与免疫治疗病区
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Jiang, Hao,Chen, Shan-Shan,Jiang, Bin,et al. Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase[J]. ANNALS OF HEMATOLOGY,2011,90(1):41-46.
APA Jiang, Hao.,Chen, Shan-Shan.,Jiang, Bin.,Jiang, Qian.,Qin, Ya-Zhen.,...&Huang, Xiao-Jun.(2011).Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase.ANNALS OF HEMATOLOGY,90(1),41-46.
MLA Jiang, Hao,et al."Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase".ANNALS OF HEMATOLOGY 90.1(2011):41-46.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jiang, Hao]的文章
[Chen, Shan-Shan]的文章
[Jiang, Bin]的文章
百度学术
百度学术中相似的文章
[Jiang, Hao]的文章
[Chen, Shan-Shan]的文章
[Jiang, Bin]的文章
必应学术
必应学术中相似的文章
[Jiang, Hao]的文章
[Chen, Shan-Shan]的文章
[Jiang, Bin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。